Page last updated: 2024-08-24

mibefradil and Hypertrophy

mibefradil has been researched along with Hypertrophy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allen, TJ; Cao, Z; Cooper, ME; Hulthén, UL	1

Other Studies

1 other study(ies) available for mibefradil and Hypertrophy

Article	Year
Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action. Journal of hypertension, 1998, Volume: 16, Issue:6 Topics: Actins; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Calcium Channels; Diabetes Mellitus, Experimental; Dihydropyridines; Hypertrophy; Male; Mesenteric Arteries; Mibefradil; Muscle, Smooth, Vascular; Peptidyl-Dipeptidase A; Ramipril; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes	1998

Article

Year

Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action.

Journal of hypertension, 1998, Volume: 16, Issue:6

Topics: Actins; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Calcium Channels; Diabetes Mellitus, Experimental; Dihydropyridines; Hypertrophy; Male; Mesenteric Arteries; Mibefradil; Muscle, Smooth, Vascular; Peptidyl-Dipeptidase A; Ramipril; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes

1998